The earnings call highlighted significant growth in YCANTH sales, strategic partnerships, and improved financial performance, although concerns about future cash flow and reduced R&D expenses were noted.

Company Guidance

During Verrica Pharmaceuticals' Second Quarter 2025 Corporate Update Conference Call, the company reported significant growth and strategic developments. Notably, the commercial team achieved a record 13,434 YCANTH dispensed applicator units, marking a 32.8% sequential increase from the prior quarter. Verrica also secured an $8 million milestone payment from Torii Pharmaceutical as part of an amended agreement to initiate a global Phase III program for YCANTH targeting common warts. Financially, the company reported total revenue of $12.7 million, up from $5.2 million in the same quarter of 2024, driven by $8 million from Torii and $4.5 million net revenue from YCANTH. Additionally, gross product margins were approximately 93%, with research and development expenses decreasing by $1.5 million, and selling, general, and administrative expenses decreasing by $7.7 million compared to the previous year. The company expressed confidence in sustained growth, bolstered by expanded geographic reach and enhanced product accessibility.

Record Growth in YCANTH Dispensed Units

Verrica Pharmaceuticals reported a record 13,434 YCANTH dispensed applicator units in Q2 2025, representing a 32.8% sequential quarterly growth over the prior quarter.

Strategic Partnership and Financial Milestone

Verrica strengthened its partnership with Torii Pharmaceutical, securing Torii's financial commitment to a global Phase III program for YCANTH and receiving an $8 million milestone payment.

Revenue Increase

Total revenue for Q2 2025 was $12.7 million, up from $5.2 million in Q2 2024, driven by milestone revenue and net YCANTH sales.

Operational Cost Management

Selling, general, and administrative expenses decreased by $7.7 million compared to Q2 2024, due to a focused commercial strategy for YCANTH.

Positive Net Income

GAAP net income was $0.2 million for Q2 2025, compared to a net loss of $17.2 million in Q2 2024.

Verrica Pharmaceuticals (VRCA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VRCA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	-0.77 / -	-4.9	―	―	―
Aug 12, 2025	2025 (Q2)	-0.90 / 0.02	-3.7	100.54% (+3.72)	―
May 13, 2025	2025 (Q1)	-1.26 / -1.00	-4.4	77.27% (+3.40)	―
Mar 11, 2025	2024 (Q4)	-2.50 / -2.40	-5.3	54.72% (+2.90)	―
Nov 04, 2024	2024 (Q3)	-3.76 / -4.90	-5.4	9.26% (+0.50)	―	―
Aug 14, 2024	2024 (Q2)	-4.14 / -3.70	-2.4	-54.17% (-1.30)	―
May 13, 2024	2024 (Q1)	-4.47 / -4.40	-1.5	-193.33% (-2.90)	―
Feb 29, 2024	2023 (Q4)	-5.62 / -5.30	-1.4	-278.57% (-3.90)	―
Nov 09, 2023	2023 (Q3)	-3.61 / -5.40	0	―	―
Aug 08, 2023	2023 (Q2)	-2.10 / -2.40	-3.7	35.14% (+1.30)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VRCA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$6.82	$6.59	-3.37%
May 13, 2025	$5.50	$5.35	-2.73%
Mar 11, 2025	$6.48	$5.99	-7.56%
Nov 04, 2024	$14.30	$7.98	-44.20%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Verrica Pharmaceuticals (VRCA) report earnings?

Verrica Pharmaceuticals (VRCA) is schdueled to report earning on Nov 10, 2025, TBA (Confirmed).

What is Verrica Pharmaceuticals (VRCA) earnings time?

Verrica Pharmaceuticals (VRCA) earnings time is at Nov 10, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VRCA EPS forecast?

VRCA EPS forecast for the fiscal quarter 2025 (Q3) is -0.77.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing